This trial is conducted in Europe. The aim of this clinical trial is to investigate whether differences exist between three different concentrations of the drug, NN9535, administered in healthy male subjects in equal doses.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
44
Comparison of different formulations of the drug, semaglutide: Formulation 1 administered in equimolar doses
Comparison of different formulations of the drug, semaglutide: Formulation 2 administered in equimolar doses
Comparison of different formulations of the drug, semaglutide: Formulation 3 administered in equimolar doses
Unnamed facility
Berlin, Germany
AUC0-8 (NN9535), the area under the plasma NN9535 plasma-concentration-time curve in the interval 0-8 after investigational medicinal product administration
Time frame: a 28 day time period
Cmax of the plasma NN9535 curve
Time frame: a 28 day time period
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.